We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes
Read MoreHide Full Article
Walgreens Boots’ (WBA - Free Report) various strategic partnerships are expected to benefit the company over the long run. However, the prevailing tough macroeconomic environment might hamper the company’s margin. The stock carries a Zacks Rank #3 (Hold).
Walgreens exited first-quarter fiscal 2023 with better-than-expected earnings and revenues. The company’s U.S. Healthcare business grew, led by key contract wins, continued partnership growth and a strong focus on execution. The company achieved the calendar year 2022 target for co-located VillageMD clinics of 200.
The company continues to play a leading role in COVID-19 vaccinations and testing, administering 8.4 million vaccinations in the reported quarter. Walgreens raised its U.S. Healthcare target in November, including the fiscal 2025 sales goal of $14.5-$16.0 billion, up from $11.0-$12.0 billion previously. Moreover, the company raised its 2023 sales guidance, reflecting continued growth momentum.
During the first-quarter fiscal 2023 earnings update, Walgreens stated that it has launched 24-hour same-day delivery, offering the widest range of retail items for around-the-clock delivery across the country. This adds to the company’s broad range of channel access, including one-hour delivery and 30-minute pickup.
In June 2022, Walgreens launched its clinical trial business to redefine the patient experience and bolster access and retention in sponsor-led drug development research. In March 2022, the company, in collaboration with Laboratory Corporation of America Holdings, announced the nationwide availability of “Pixel by LabCorp COVID-19 at-home collection kit” at no cost to individuals who meet clinical guidelines.
In terms of new partnerships, in November 2022, VillageMD entered into a definitive agreement to acquire Summit Health-CityMD — a leading provider of primary, specialty and urgent care.
In October 2022, Walgreens announced the acceleration of its plans to acquire full ownership of CareCentrix, expanding its reach into the growing homecare sector and advancing its healthcare long-term growth strategy.
On the flip side, over the past year, Walgreens has underperformed the industry. The stock has lost 23.2% compared with the industry’s 9.7% decline.
During the first quarter of fiscal 2023, Walgreens’ Pharmacy sales decreased 4.2% compared with the year-ago quarter, negatively impacted by a 7.8 percentage point headwind from AllianceRx Walgreens. Comparable pharmacy sales declined 0.9%, reflecting lower demand for COVID-19 services. The International segment declined year over year due to an adverse currency impact of 15.4%.
In the last few years, the slowdown in generic introduction has been affecting Walgreens’ margins. In addition, increased reimbursement pressure and generic drug cost inflation have been hampering its margin on a significant level. In the first quarter of fiscal 2023, gross profit fell 8.2% year over year. Gross margin contracted 152 basis points to 20.8%. Selling, general and administrative expenses were up 105.9%. The company reported an adjusted operating loss of $6.2 million for the quarter under review against $1.3 million of operating profit in the year-ago period.
Key Picks
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , McKesson Corporation (MCK - Free Report) and Avanos Medical, Inc. (AVNS - Free Report) .
Hologic, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 15.2%. HOLX’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 30.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic has gained 10.9% against the industry’s 14.7% decline in the past year.
McKesson, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.4%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 3.4%.
McKesson has gained 23.3% against the industry’s 9.2% decline over the past year.
Avanos, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1.8% for 2023. AVNS’ earnings surpassed estimates in all the trailing four quarters, the average beat being 11%.
Avanos has lost 17.6% compared with the industry’s 14.7% decline over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes
Walgreens Boots’ (WBA - Free Report) various strategic partnerships are expected to benefit the company over the long run. However, the prevailing tough macroeconomic environment might hamper the company’s margin. The stock carries a Zacks Rank #3 (Hold).
Walgreens exited first-quarter fiscal 2023 with better-than-expected earnings and revenues. The company’s U.S. Healthcare business grew, led by key contract wins, continued partnership growth and a strong focus on execution. The company achieved the calendar year 2022 target for co-located VillageMD clinics of 200.
The company continues to play a leading role in COVID-19 vaccinations and testing, administering 8.4 million vaccinations in the reported quarter. Walgreens raised its U.S. Healthcare target in November, including the fiscal 2025 sales goal of $14.5-$16.0 billion, up from $11.0-$12.0 billion previously. Moreover, the company raised its 2023 sales guidance, reflecting continued growth momentum.
During the first-quarter fiscal 2023 earnings update, Walgreens stated that it has launched 24-hour same-day delivery, offering the widest range of retail items for around-the-clock delivery across the country. This adds to the company’s broad range of channel access, including one-hour delivery and 30-minute pickup.
In June 2022, Walgreens launched its clinical trial business to redefine the patient experience and bolster access and retention in sponsor-led drug development research. In March 2022, the company, in collaboration with Laboratory Corporation of America Holdings, announced the nationwide availability of “Pixel by LabCorp COVID-19 at-home collection kit” at no cost to individuals who meet clinical guidelines.
Walgreens Boots Alliance, Inc. Price
Walgreens Boots Alliance, Inc. price | Walgreens Boots Alliance, Inc. Quote
In terms of new partnerships, in November 2022, VillageMD entered into a definitive agreement to acquire Summit Health-CityMD — a leading provider of primary, specialty and urgent care.
In October 2022, Walgreens announced the acceleration of its plans to acquire full ownership of CareCentrix, expanding its reach into the growing homecare sector and advancing its healthcare long-term growth strategy.
On the flip side, over the past year, Walgreens has underperformed the industry. The stock has lost 23.2% compared with the industry’s 9.7% decline.
During the first quarter of fiscal 2023, Walgreens’ Pharmacy sales decreased 4.2% compared with the year-ago quarter, negatively impacted by a 7.8 percentage point headwind from AllianceRx Walgreens. Comparable pharmacy sales declined 0.9%, reflecting lower demand for COVID-19 services. The International segment declined year over year due to an adverse currency impact of 15.4%.
In the last few years, the slowdown in generic introduction has been affecting Walgreens’ margins. In addition, increased reimbursement pressure and generic drug cost inflation have been hampering its margin on a significant level. In the first quarter of fiscal 2023, gross profit fell 8.2% year over year. Gross margin contracted 152 basis points to 20.8%. Selling, general and administrative expenses were up 105.9%. The company reported an adjusted operating loss of $6.2 million for the quarter under review against $1.3 million of operating profit in the year-ago period.
Key Picks
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , McKesson Corporation (MCK - Free Report) and Avanos Medical, Inc. (AVNS - Free Report) .
Hologic, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 15.2%. HOLX’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 30.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic has gained 10.9% against the industry’s 14.7% decline in the past year.
McKesson, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.4%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 3.4%.
McKesson has gained 23.3% against the industry’s 9.2% decline over the past year.
Avanos, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1.8% for 2023. AVNS’ earnings surpassed estimates in all the trailing four quarters, the average beat being 11%.
Avanos has lost 17.6% compared with the industry’s 14.7% decline over the past year.